Pfizer agreed to buy Array BioPharma for $10.64 billion in cash, as the pharmaceutical company looks to expand its pipeline of cancer therapies
Pfizer Inc. agreed to buy Array BioPharma Inc. for $10.64 billion in cash, as the pharmaceutical company looks to expand its pipeline of cancer therapies.
Pfizer said it would pay Array shareholders $48 for each of its shares outstanding, a 62% premium to the closing price Friday. Pfizer said it would fund the transaction with debt and existing cash.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Pfizer to buy cancer drug developer Array Biopharma for $10.64 billionPfizer said on Monday it had agreed to acquire Array Biopharma for $10.64 billion, which will grant it access to its cancer drugs.
Consulte Mais informação »
There’s No Room For Cupholders In Uber’s Vision For Electric Air TaxisFlight information screens, storage areas, charge points -- Uber and Safran initially envisioned an array of passenger comforts for a concept air taxi cabin design. And then they removed it all, the better to speed passengers in and out.
Consulte Mais informação »
Pfizer to buy cancer drug developer Array Biopharma for $10.64 billionPfizer said on Monday it had agreed to acquire Array Biopharma for $10.64 billion, which will grant it access to its cancer drugs.
Consulte Mais informação »
Billionaire Patrick Drahi agrees to buy Sotheby's in $3.7 billion dealPatrick Drahi, the billionaire behind telecoms and media group Altice, agreed on...
Consulte Mais informação »
Rupert Murdoch Buys $21.2M In Fox Corp. Stock A Week After Buying “In Error”Fox Corp. executive chairman Rupert Murdoch bought shares in the company worth $21.2 million about a week after buying a similar amount “in error” and then quickly selling it again. Acc…
Consulte Mais informação »
We're launching Digital Health Pro — here's how to access insights from healthcare's biggest decision-makersDigital Health Pro is Business Insider Intelligence’s newest expert product suite for industry-changing digital health news and analysis. Learn more now:
Consulte Mais informação »